Director at Organogenesis (ORGO) receives 48,828 restricted stock units

Rhea-AI Filing Summary

Organogenesis Holdings Inc. director Garrett Lustig reported an equity award from the company. He acquired 48,828 shares of Class A common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share, bringing his direct holdings to 125,742 shares.

Each RSU represents the right to receive one share of Organogenesis Class A common stock upon vesting. According to the grant terms, all of these RSUs vest in full on February 15, 2027, aligning Lustig’s compensation with the company’s long-term performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lustig Garrett

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	48,828	$0.00	--

Holdings After Transaction: Class A Common Stock — 125,742 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lustig Garrett

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A(1)		48,828	A	$0	125,742	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.

	/s/ William R. Kolb, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Organogenesis (ORGO) director Garrett Lustig report?

Garrett Lustig reported receiving an equity award from Organogenesis. He was granted 48,828 restricted stock units, each convertible into one share of Class A common stock, increasing his direct holdings to 125,742 shares after the award was recorded.

How many Organogenesis (ORGO) shares did Garrett Lustig acquire in this Form 4?

Garrett Lustig acquired 48,828 shares of Organogenesis Class A common stock through a grant of restricted stock units. The award was reported at a price of $0.00 per share and raised his directly owned stake to a total of 125,742 shares.

What are the vesting terms of Garrett Lustig’s Organogenesis (ORGO) RSU grant?

The restricted stock units granted to Garrett Lustig vest in full on February 15, 2027. Each RSU represents a contingent right to receive one share of Organogenesis Class A common stock once vested, tying the award’s value to future company performance and time-based service.

What type of security was reported in Garrett Lustig’s Organogenesis (ORGO) Form 4?

The Form 4 reports Class A common stock linked to a restricted stock unit grant. Each RSU entitles Lustig to receive one share of Organogenesis Class A common stock upon vesting, as described in the equity award’s footnote disclosure.

Was Garrett Lustig’s Organogenesis (ORGO) equity award a market purchase or a grant?

The transaction was a grant, not a market purchase. Form 4 shows transaction code “A” for a grant, award, or other acquisition, with 48,828 restricted stock units awarded at $0.00 per share under the company’s 2018 Equity Incentive Plan.